Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Nitrosamines topic
No spam. Unsubscribe anytime.
FDA presenter outlines nitrosamine carcinogenic mechanism and risk framework
Summary
An FDA agency official described nitrosamines’ carcinogenic mechanism—requiring metabolic activation to form DNA-reactive intermediates—and said the class is treated as a cohort of concern under ICH M7, with lifetime exposure benchmarks used to limit cancer risk.
An FDA agency official opened the briefing by saying the talk would cover nitrosamine safety assessment, common pitfalls in submissions, and recommendations for applicants.
"The term of nitrosamine refers to both small molecule nitrosamines and the complex nitrosamines," the presenter said, distinguishing small molecules (well-studied rodent carcinogens) from complex nitrosamine drug-substance–related impurities. The presenter explained that small-molecule nitrosamines require metabolic activation—specifically alpha hydroxylation—to form DNA adducts that can cause gene mutation and early tumor formation. The official added that nitrosamines are treated as a "cohort of concern in ICH M7" and therefore require tighter control than typical mutagenic impurities.
The presenter highlighted that the agency applies a lifetime exposure benchmark intended to correspond roughly to a 1-in-100,000 excess cancer risk and that FDA uses structural and metabolic considerations when setting acceptable intake (AI) limits. The briefing framed nitrosamine assessment around mechanistic toxicology, available carcinogenicity data and conservative risk-management choices.
